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ABSTRACT
Platelet derived growth factor receptors (PDGFRs) play an important role in 
tumor pathogenesis, and they are frequently overexpressed in glioblastoma (GBM). 
Earlier we have shown a higher protein expression of PDGFR isoforms (α and β) in 
peritumoral-tissue derived cancer stem cells (p-CSC) than in tumor core (c-CSC) of 
several GBM affected patients. In the current study, in order to assess the activity of 
PDGFRα/PDGF-AA signaling axis, we performed time course experiments to monitor 
the effects of exogenous PDGF-AA on the expression of downstream target genes 
in c-CSC vs p-CSC. Interestingly, in p-CSC we detected the upregulation of Y705-
phosphorylated Stat3, concurrent with a decrement of Rb1 protein in its active 
state, within minutes of PDGF-AA addition. This finding prompted us to elucidate 
the role of PDGFRα in self-renewal, invasion and differentiation in p-CSC by using 
short hairpin RNA depletion of PDGFRα expression. Notably, in PDGFRα-depleted 
cells, protein analysis revealed attenuation of stemness-related and glial markers 
expression, alongside early activation of the neuronal marker MAP2a/b that correlated 
with the induction of tumor suppressor Rb1. The in vitro reduction of the invasive 
capacity of PDGFRα-depleted CSC as compared to parental cells correlated with the 
downmodulation of markers of epithelial-mesenchymal transition phenotype and 
angiogenesis. Surprisingly, we observed the induction of anti-apoptotic proteins and 
compensatory oncogenic signals such as EDN1, EDNRB, PRKCB1, PDGF-C and PDGF-D. 
To conclude, we hypothesize that the newly discovered PDGFRα/Stat3/Rb1 regulatory 
axis might represent a potential therapeutic target for GBM treatment.
INTRODUCTION
Among the different types of adult brain tumors, 
glioblastoma multiforme (GBM) is the most aggressive 
and angiogenic, but despite the efforts to find effective 
treatments, these tumors remain incurable [1]. The 
amplification and/or overexpression of either EGFR or 
PDGFR can contribute to the malignant phenotype of 
distinct subsets of human glioblastoma [2]. More recently, 
a classification of GBM in subclasses has been defined for 
the selection of the best-tailored therapeutic approaches 
[3, 4]. Platelet-derived growth factors (PDGFs) isoforms 
and receptors (PDGFRs) have important functions in the 
regulation of growth and survival of certain cell types 
during embryonal development and in control of tissue 
homeostasis in the adult [5]. A wide range of work from 
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in vitro studies to mouse models have implicated the role 
of the PDGF pathway in cellular invasion and tumor 
angiogenesis [6]. In fact, over-activity of PDGF signaling 
is associated with tumor development in brain, prostate, 
liver, lung, leukemia and colon cancers [7, 8]. Although 
anti-VEGF treatment has been the major therapeutic 
target in gliomas, other antiangiogenic agents such as 
anti-PDGFs or anti-FGFs are currently in preclinical and 
clinical development [9]. PDGFR includes two receptors 
(α and β) and four ligands (PDGF-A, PDGF-B, PDGF-C 
and PDGF-D). The PDGFs bind to the receptors with 
different affinities. Thus, PDGF-AA, -AB, -BB and -CC 
induce αα receptor homodimers, PDGF-BB and -DD ββ 
receptor dimerization, and PDGF-AB, -BB, -CC and -DD 
αβ receptor dimerization [5]. Ligand-induced dimerization 
favors autophosphorylation of specific tyrosine residues 
and subsequent activates downstream signal pathways: 
PI3K/Akt1/mTOR, Ras/MAPK, PLC-γ/PKC and STAT3. 
PDGFR binds and activates signal transducers and activator 
of transcription (STATs). Phosphorylation of Y705 in Stat3 
leads to dimerization, nuclear translocation, recognition of 
Stat3-specific DNA binding elements and up-regulation 
of various Stat3 downstream target genes, such as Bcl-xl, 
Bcl-2, Survivin, c-Myc and Cyclin D1. Stat3 regulates 
tumorigenesis and tumor inflammation and behaves in an 
oncogenic manner depending on the genetic background of 
the tumor [1]. In recent studies, Stat3 has been implicated in 
the self-renewal of neural stem cells and glial differentiation 
while restricting neuronal differentiation [8–13].
The PKC family consists of fifteen isozymes divided 
into three subfamilies: conventional (or classical), novel, 
and atypical. Conventional PKCs contain the isoforms α, 
βI, βII, and γ. The PDGFR downstream target PKCα plays 
an important role in migration, tumor growth, angiogenesis 
and drug resistance in GBM cells [14–16]. In 1992, PKCα 
was suggested as marker of malignancy for gliomas, and 
more recently serum PKCα serves as a biomarker for 
diagnosis of cancers [14, 15]. The invasion/migration of 
GBM cells induced by TPA, occurs through activation of 
PKCα/ERK/NF-κB-dependent MMP-9 expression [16]. 
A positive feedback loop between Wnt5A and phospho-
PKC in promotion of epithelial-mesenchymal transition 
(EMT) in nasopharyngeal carcinoma was disclosed [17]. 
In addition, PDGF receptors bind to other tyrosine kinase 
receptors, e.g. EGFR [18]. Retinoblastoma 1 (RB1) gene 
belongs to a family of three proteins, including also RBL1/
p107 and RBL2/p130. Classically the tumor suppressive 
function of Rb proteins have been mainly attributed to 
their ability to arrest cell cycle by repressing E2F target 
genes. When Rb1 is in its active hypophosphorylated state, 
it represses E2F-mediated transcription by binding, blocks 
the E2F transactivation domain, and forms complexes with 
its (DPs transcription factors) partners at cell cycle gene 
promoters [19]. Conversely, Rb1 phosphorylation initiated 
by cyclin D-CDK4/6 in response to mitogenic signals, 
inactivates the Rb1 repressive function by dissociating 
the Rb1-E2F-DP complexes [19]. The Cancer Genome 
Atlas Research Network revealed in 2008 that the CycD1-
CDK4/6-Rb1 pathway is among the top three most altered 
pathways in GBM, which makes this an appealing target 
for cancer therapy [20–22].
We and others recently demonstrated that inhibition 
of either PDGFRα or PDGFRβ signaling induced apoptosis 
in glioblastoma stem cells [23, 7]. In the present study, 
we aimed to assess the effects of PDGFRα depletion on 
stemness, invasion and differentiation in GBM CSC. Our 
findings reveal an inverse correlation between Stat3 Y705-
phosphorylation and the hypophosphorylated Rb1 instructed 
by the PDGFRα/PDGF-AA regulatory axis. Further, 
downmodulation of cell growth, invasion and the EMT 
phenotype are triggered by PDGFRα depletion in GBM 
CSC. Surprisingly, we detected the activation of angiogenic 
and survival pathways as compared to parental cells, which 
supports a multimodal approach to treat GBM CSC.
RESULTS
Activation of PDGFRα/PDGF-AA signaling 
regulates expression of downstream genes Egr1, 
Stat3 and Rb1 but not PKCα in GBM CSC
Cancer stem cells from GBM were isolated as 
described previously [23, 24]. We were able to collect either 
core- (c-CSC) or peritumor tissue-derived cancer stem 
cells (p-CSC) from several primary GBM samples; the two 
types of CSC had quite different tumorigenic potential and 
exclusive genetic anomalies [23, 24]. To demonstrate that 
the high expression of PDGFRα in p-CSC2 [23], confers a 
higher PDGF response than in c-CSC2, both cell types, were 
growth factors starved and then, exposed to exogenous PDGF-
AA (50 ng/ml) over a time course. In these experimental 
conditions (Figure 1A), we found more rapid activation of 
p-Erk1/2 in p-CSC2 than in c-CSC2 as reported previously 
[23]. Moreover, Egr1 (Early growth response 1) protein 
and Stat3 Y705 phosphorylation were induced as early as 5 
minutes after PDGF-AA stimulation (Figure 1A). Strikingly, 
we noted a tight correlation between this phosphorylation 
event and the transient decrement of the tumor suppressor 
Rb1 in its active state, that occurred within 10 minutes, as 
detected by a monoclonal antibody that specifically recognizes 
hypophosphorylated active Rb1 (hypo-Rb1). A densitometric 
analysis (data not shown) showed a 70% signal reduction 
at this time point compared to time point zero, followed by 
a gradual recovery. The engagement of PDGFRα with its 
ligand induced the gradual disappearance of the receptor 
2 hours after PDGF-AA stimulus. The high expression and 
phosphorylation of PKCα/βII isoforms was not altered by 
PDGF-AA stimulation in either cell populations (Figure 1A).
Block of PDGFRα activity by Crenolanib reduces 
the phosphorylation of Rb1 and Stat3 Y705
To assess whether the decrement of hypo-Rb1 
was PDGFRα/PDGF-AA axis-dependent, a time course 
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experiment was performed to evaluate the effects 
of PDGF-AA applied alone or in combination with 
Crenolanib (CR, a potent inhibitor of PDGFR signaling), 
on p-CSC2 two days after growth factors withdrawal. Rb1 
phosphorylation was monitored at short time intervals (5-
10-30-120 minutes) up to 24 after the start of PDGF-AA 
stimulation. CR-treated cells showed upregulation of the 
hypo-Rb1 between 5 and 30 minute after the treatment as 
compared to PDGF-AA alone. A densitometric analysis 
(data not shown) showed an increase of 50% of hypo-
Rb1 signal within the first half hour in CR-treated cells 
compared to PDGF-AA alone. Two hours after the 
treatments the levels of the hypo-Rb1 return to baseline 
(Figure 1C). In contrast, Stat3 Y705 phosphorylation 
remained silenced at 24 hours by CR treatment (Figure 
1B). Previous studies showed that the epidermal growth 
factor receptor (EGFR) could be transactivated by PDGFs 
stimulation and that EGFR transactivation was required 
for PDGF-stimulated cell migration [18]. In corroboration, 
we showed that PDGF-AA induced EGFR Y1068-
phosphorylation, and EGFR transactivation was inhibited 
by Crenolanib treatment (Figure 1B). CR was also found 
to upregulate Erk1/2 downstream of both the PDGFR and 
the EGFR (Figure 1B).
shPDGFRα-GBM CSC display changes in 
cell morphology and EMT phenotypes, which 
correlate with modifications in the molecular 
profile
To demonstrate the central role of PDGFRα in 
CSC proliferation and differentiation, we interfered 
with PDGFRα gene expression using short hairpin RNA 
(shRNA) sequences transduced by a lentivirus-based 
system. We selected two PDGFRα-directed shRNA clones 
(1 and 3) of p-CSC2 that displayed a robust silencing of 
Figure 1: Activation of PDGFRα/PDGF-AA axis induces different modulation of target genes in GBM p-CSC2 than 
in c-CSC2. A. Time course experiment of the effects of PDGF-AA on immediate early genes activation in c-CSC2 vs p-CSC2 after 2 
days of growth factors starvation. p-CSC2 express Egr1 and Y705-phosphorylated Stat3 after 5 minutes, on the other hand, hypo-Rb1 is 
significantly downmodulated in p-CSC2 after 10 minutes of treatment. Instead, the levels of T638/641-PKCα/βII remain stable at all time 
points. B. PDGF-AA applied alone or with CR for 24 hours on p-CSC2. Stat3 Y705 phosphorylation levels are impaired by CR treatment, 
instead hypo-Rb1 and total Rb1 protein expression are not affected after 24 hours by PDGFR inhibition. Cyclin D1 protein levels are not 
modulated in the same conditions. β-actin is used as control of equal proteins loading. C. Time course experiment to evaluate the effects of 
PDGF-AA alone or combined with CR on the regulation of hypo-Rb1 in p-CSC2. CR upregulates hypo-Rb1 expression respect to PDGF-
AA alone.
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PDGFRα compared to transduced control cells (pLKO.1) 
(Figure 2A). Depletion of PDGFRα expression was 
associated with a reduction in cell growth as reported 
previously [23], and with a concomitant impairment of 
neurosphere formation ability, consistently observed over 
the entire seven days of time course (Figure 3). The two 
cell clones showed evident morphological changes if 
induced to differentiate in presence of 5% FCS. After 2 
and 4 days in differentiation conditions, shPDGFRα-CSC 
showed an epithelial cell morphology, with formation 
of adherent cell clusters and few cells with an elongated 
phenotype. In contrast, the pLKO.1 control cells showed 
a flat morphology with a clear mesenchymal phenotype, 
evenly distributed on the plate (Figure 4). These 
observations prompted us to explore the gene expression 
of epithelial cell junction proteins such as E-cadherin 
(CDH1) and VE-Cadherin (CDH5) or ECM molecules 
such as fibronectin (FN1) by a RT-qPCR analysis. CDH1 
mRNA expression was monitored in PDGFRα-depleted 
CSCs during cell proliferation. Both clone 1 and 3 showed 
higher expression compared with control cells, with a 
fold change of 13.1 and 13.6 respectively in proliferating 
cells and with a peak of activation at 15.2 and 17.3 Fc 
after 4 days of differentiation (Figure 5). Our finding 
were consistent with that published in various cell lines, 
reporting an inverse correlation between CDH1 expression 
and invasiveness [25]. CDH5 mRNA levels were 
drastically downmodulated in proliferating cell clones 
and reached 0.35 and 0.36 Fc in 4 days-differentiated cells 
respectively (Figure 5). Similarly, FN1 mRNA expression 
Figure 2: Modulation of multipotency, differentiation and survival markers in PDGFRα-depleted GBM CSC vs control 
cells. A. Western blot analysis reveals that depletion of PDGFRα in p-CSC2 induces the downmodulation of Stat3 Y705 phosphorylation 
in both proliferating cell clones, instead their levels raised up in differentiation conditions. The hypo-Rb1 levels result overexpressed in 
clone 3 in all conditions. Instead the clone 1, shows an increase of hypo-Rb1 at 2 and 4 day of differentiation with respect to pLKO.1 
cells. In parallel, Bcl-2 and Bcl-xL proteins and Erk1/2 pathway were upregulated in both cell clones in comparison with pLKO.1 cells in 
differentiaton conditions. T638/641 phosphorylated-PKCα/βII isoforms expression levels are slightly induced in proliferating PDGFRα-
depleted cell clones, but negatively modulated in differentiated ones than pLKO.1 cells. B. The downmodulation of multipotent protein 
markers (Nestin, Sox2, Bmi1), except for Oct4, is accompanied with early induction of the neuronal marker MAP2a/b in proliferating 
PDGFRα-depleted cell clones vs pLKO.1. Similar results were observed during cell differentiation, except for MAP2a/b that increases in 
pLKO.1 with respect to PDGFRα-depleted cells.
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was diminished to 0.34 and 0.38 fold in proliferating 
shPDGFRα-CSC clones compared to pLKO.1, and went 
down to 0.16 and 0.15 Fc in 2 days-differentiated cells. 
Similar results were seen at 4 days (Figure 5). As reported 
by the literature, the combined loss of CDH1, and the 
gain of mesenchymal markers, such as vimentin, FN1 and 
N-cadherin favor the EMT program [26].
PDGFRα depletion downmodulates stemness-
related and glial markers, induces early 
expression of neuronal marker and RB1 but does 
not affect PKCα in GBM p-CSC
To assess the role of PDGFRα in the regulation 
of stemness of GBM CSC, we carried out Western blots 
and RT-qPCR to elucidate the effects of a diminished 
PDGFRα expression on stemness-related genes. We 
observed a decrease in protein expression for Nestin, 
Sox2, Bmi1, but no modulation of Oct4 (Figure 2B). 
RT-qPCR analysis confirmed the decrease of SOX2 
mRNA to 0.11 and 0.13 fold in clone 1 and 3 compared 
to control cells. Similar results were confirmed at 2 and 
4 days-differentiated p-CSC2 (Figure 5). Attenuation of 
stemness in shPDGFRα-CSC clones correlated with early 
induction of late neuronal differentiation marker MAP2a/b 
protein in proliferating cells (Figure 2B), also monitored 
as mRNA (data not shown). Genetic and pharmacological 
depletion of PDGFRα triggered the activation of tumor 
suppressor RB1 gene, a key factor controlling cell cycle 
exit and differentiation in several cell models. As shown in 
Figure 5, PDGFRα-depleted CSC clone 1 and 3 displayed 
the induction of RB1 mRNA up to 2.35 and 2.59 fold 
respectively compared to control cells. Expression levels 
raised a peak to 3.59 and 3.45 Fc in 4 days-differentiated 
Figure 3: Neurospheres formation impairment of PDGFRα-depleted GBM CSC vs control cells. Microscopic analysis at 
3 and 7 days in growth conditions reveals a diminished ability of p-CSC2 depleted of PDGFRα to make neurospheres in vitro compared to 
control cells (pLKO.1) over the entire course of the experiment.
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cells respectively. Western blot analysis revealed the 
increase of hypo-Rb1 in proliferating clone 3, or in 
both differentiated clones compared to pLKO.1 (Figure 
2A). Under the same culture conditions, we noticed a 
decrease of Stat3 Y705-phosphorylation in both clones in 
comparison to pLKO.1 cells (Figure 2A). Conversely, we 
reported a diminished expression of glial fibrillary acidic 
protein (GFAP) and the chondroitin sulfate proteoglycan 
NG2 (Figure 2B). The latter is probably the result of 
lack of a physical association with PDGFRα, which is 
an obstacle to the formation of new oligodendroglial 
precursors NG2+ve [28]. The reduced PDGFRα 
expression correlated with higher levels of Bcl-2 and 
Bcl-xL compared to control cells, suggesting a potential 
role of these genes in cell survival in either proliferating 
or differentiated cells. These results paralleled with an 
increase in CycD1 protein in differentiated cells and a 
slight decrease in proliferating cells. The latter effect 
likely correlated to cell proliferation impairment induced 
by PDGFRα deletion. Because of the critical role of PKCα 
in promoting EMT phenotype and malignant progression 
of glioblastoma cells, we hypothesized that PKCα could 
regulate stemness of GBM CSC downstream of the 
PDGFRα signaling cascade. To answer the question, we 
performed shRNA targeting of PKCα expression in 
GBM p-CSC2. The results revealed no variation of the 
multipotent stem cells markers Nestin or Sox2, even with 
the addition of PDGF-AA for three days (Figure S1). This 
finding reveals that PKCα is probably not involved in 
regulation of stemness through the PDGFRα signaling.
PDGFRα depletion inhibits the invasiveness 
of GBM CSC and triggers EDN1 signaling, 
PDGF-C and PDGF-D expression
Formerly we reported that GBM p-CSC2 displayed 
higher invasive capacity through Matrigel with respect to 
the counterpart c-CSC2 [23]. Herein, we aim to demonstrate 
Figure 4: PDGFRα-depleted GBM CSC show phenotypic changes vs control cells. Phase-contrast images captured after 
1-2-4 days in differentiation conditions revealed morphological changes between shPDGFRα-CSC clone 1 and clone 3 in comparison with 
pLKO.1. The aspect of pLKO.1 cells is more similar to the mesenchymal phenotype with a flat cell morphology. Conversely, the shPDGFR-
CSC cell clones displayed an epithelial appearance with crowded cell clusters among few elongated cells, which is clear manifested at 4 
days of the cell differentiation.
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the role of PDGFRα/PDGF-AA axis in the regulation of 
the invasive capacity of p-CSC2. Using an in vitro cell 
invasion assay we demonstrated a significant reduction 
in PDGF-AA stimulated invasion of shPDGFRα-CSC 
clones compared to pLKO.1. Demonstrating specificity, no 
difference in the invasive capacity was observed using EGF 
as chemoattractant (Figure 6A). The EMT leads to a reduced 
cellular adhesion, changes in cytoskeletal organization and 
acquired potential for cell migration, all this process is 
associated to changes in expression of transcription factors 
[30]. To corroborate the role of PDGFRα on the invasive 
phenotype of p-CSC2, we completed the RT-qPCR analysis 
of critical genes for EMT such as ZEB1, ZEB2, TWIST1 
and Vimentin (VIM). Our results displayed a significant 
Figure 5: PDGFRα deletion induces different expression of target genes in GBM CSC in proliferation and differentiation 
conditions. RT-qPCR analysis shows a significant modulation of gene expression of cell-cell (CDH1, CDH5) and cell-substrate (FN1) 
molecules interactions, the stem cell marker SOX2 and oncogenic signaling molecules (PRKCA, PRKCB1). Progressive upregulation 
of the tumor suppressor RB1 and PRKCB1 isoform during cell differentiation is shown. Results represent the mean of two independent 
experiments performed in triplicate. Fold change (Fc).
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decrease of VIM, ZEB1, ZEB2, but not TWIST1 in 
both proliferating cell clones (Figure 6B). Similarly, we 
noticed a decrease of angiogenic markers (Figure 6B) 
such as VEGFR2, PECAM1 (CD31), and CDH5 as shown 
previously (Figure 5). In parallel, Western blot analysis 
display a significant decrease of CD31, VEGFR2 and VE-
Cadherin proteins, corroborating mRNA expression levels 
(Figure 6C). Unexpectedly, we noticed an increase of 
mRNA expression for endothelin1 (EDN1), the receptor 
EDNRB (Figure 6B), its target gene PRKCB1, but not 
PRKCA (Figure 5). In Figure 5 we reported a significant 
upregulation of PRKCB1 gene expression in proliferating 
(79.4 and 78.9 Fc respectively) and differentiated PDGFRα-
depleted cell clones 1 and 3 (86.3 and 71.8 Fc respectively) 
compared with pLKO.1. Instead, PRKCA gene expression 
was slightly reduced either in proliferating (0.78 and 0.86 
Fc respectively) or differentiated PDGFRα-depleted cell 
clone 1 and 3 (0.7 and 0.8 Fc respectively). Consistently, 
PKCα protein expression and phosphorylation of PKCα/
βII isoforms are reduced in differentiation conditions 
in cell clones compared to pLKO.1 (Figure 2A). In as 
much as peritumor tissue-derived CSC presented greater 
chemoresistance to treatments respect to core tumor 
derived-CSC [23], we decided to investigate by RT-qPCR 
the expression of the main modulators of EMT and/or drug 
resistance such as TWIST, EDN1 and PRKCA in several 
samples of GBM CSC (Figure 7B). We observed a slight 
increase of PRKCA in p-CSC compared to respective c-CSC 
pools, except for CSC5. EDN1 and TWIST expression levels 
were upregulated several fold in the majority of p-CSC in 
comparison to c-CSC (Figure 7A). We examined the mRNA 
expression profile of PDGF ligand isoforms in PDGFRα-
depleted cells. Interestingly, we noticed that PDGF-C and 
PDGF–D were highly expressed in proliferating PDGFRα-
depleted CSC as compared to pLKO.1 cells. PDGF-C 
reached 2.8 and 3.2 Fc in proliferating clone1 and 3 
Figure 6: shPDGFRα-CSC clones display a significant reduction of invasiveness and angiogenesis compared to 
pLKO.1. A. In the absence of growth factors (Stem Medium) all cells display the same invasive capacity. Addition of EGF promoted 
invasiveness in both cell clone 1 and 3 vs pLKO.1 cells. PDGF-AA addition significantly promoted pLKO.1 cells invasion but does not 
affect p-CSC2 shPDGFRα cell clones invasiveness. B. RT-qPCR analysis of key genes for angiogenesis and EMT. PECAM1, VEGFR2 are 
dramatically repressed in p-CSC2 shPDGFRα clone 1 and 3 with respect to pLKO.1. EDN1 and its receptor EDNRB are upregulated in 
PDGFRα-depleted cells compared to pLKO.1. The main EMT markers such as ZEB1, ZEB2 and VIM, except for TWIST, are significantly 
downmodulated in PDGFRα-depleted cells compared to pLKO.1 cells. Error bars represent the mean ± SD of two independent experiments 
performed in triplicate. *, P<0.05, **, P<0.01**, ***, P<0.001 vs. control. C. Western blot analysis for endothelial markers in p-CSC2 
shPDGFRα clone 1 and 3 with regard to pLKO.1. A significant decrease is reported for CD31, VEGFR2 and VE-cadherin proteins in 
PDGFRα-depleted cell vs control cells.
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respectively, while PDGF-D reached a peak of 8.3 and 8.9 
Fc respectively. At 2 and 4 days-differentiated cells these 
values were significantly higher: PDGF-C reached a peak 
at day 4 with 8.5 and 8.7 Fc in clone 1 and 3 respectively, 
instead PDGF-D raised up to 13.8 and 16.8 Fc respectively 
as compared with pLKO.1 (Figure 7B).
DISCUSSION
Our work aimed to assess the role of PDGFRα 
signaling in self-renewal, differentiation, invasion 
and EMT phenotype in glioblastoma CSC through the 
knockdown of PDGFRα expression. Previous studies 
showed that either genetic or pharmacological targeting 
Figure 7: RT-qPCR analysis of EMT markers in several GBM CSCs and of PDGF isoforms profile in pCSC2 shPDGFRα 
vs pLKO.1. A. We compared several GBM p-CSCs vs the respective GBM c-CSCs for EDN1, PRKCA and TWIST mRNA expression. B. 
mRNA expression profile of PDGF isoforms highlights the elevated induction of PDGF-C and PDGF-D in p-CSC2 shPDGFRα vs pLKO.1 
either in proliferating or differentiated cells. Results represent the mean of two independent experiments performed in triplicate.
Oncotarget10www.impactjournals.com/oncotarget
of PDGFRβ or PDGFRα inhibited self-renewal, survival, 
tumor growth and invasiveness of GBM CSC [7, 23]. 
Overexpression of PDGFRα in p-CSC of six GBM cases 
published previously by our group prompted us to make 
the hypothesis that peritumor tissue-derived GBM CSC 
might be more responsive to inhibition of PDGFR activity 
[23]. In fact, we have shown that a highly potent inhibitor 
of PDGFR activity, Crenolanib, induced apoptosis in 
several GBM CSC (p-CSC and c-CSC) which increased 
in combination with the inhibition of EGFR activity [23].
In order to understand the meaning of PDGFRα 
overexpression in GBM p-CSC2, we tested the effects 
of PDGF-AA stimulation on expression of canonical 
target pathways such as Erk1/2, Stat3, Egr1. Transient 
Stat3 activation occurred at early time points and, it 
was subsequently turned off. At later time points, Stat3 
activation was once more increased. This latter effect 
is most likely indirect and it is mediated by progrowth 
signals triggered by PDGFRα/PDGF-AA positive 
loop. In the same experiment, we observed a transient 
downmodulation of hypo-Rb1, which represents 
inactivation of the tumor suppressive function of 
Rb1 downstream of the PDGFRα/PDGFAA axis. The 
subsequent recovery of hypo-Rb1 expression correlated 
with a decrease in PDGFRα expression. The block of 
PDGFRα activity by Crenolanib also increased the 
hypo-Rb1 levels with respect to PDGF-AA alone, and 
returned to steady state levels at later time points. This 
observation suggests that Rb1 and PDGFR signaling are 
interconnected to control cell fate, but more experiments 
are warranted to elucidate the molecular mechanisms of 
this relationship.
The induction of the transcription factor Egr1, a 
member of a zinc-finger transcription factor family, goes 
in the direction of an oncogenic regulatory loop directed 
by PDGF-AA. Accordingly Sakakini et al. reported that 
the nuclear expression of Egr1 is restricted to proliferating 
cells in high-grade gliomas, and in primary cultures of 
glioma stem-like cells, Egr1 contributes to stemness 
marker expression and proliferation by orchestrating a 
PDGF-AA-dependent growth stimulatory loop [28].
A prominent effect induced by PDGFRα depletion in 
GBM CSC was cell growth impairment and an associated 
reduction in ability of GBM CSC to make neurospheres 
in vitro. PDGFRα deletion also contributed to a reduced 
expression of stemness-associated genes as well as the 
downmodulation of EMT and angiogenic markers. A 
schematic representation of biological and molecular 
effects triggered by silencing of PDGFRα in GBM CSC is 
shown (Figure 8). EMT is a physiological process occuring 
during embryogenesis that appears to be reinstated under 
certain pathological conditions, such as cancer. In the 
EMT process, epithelial cells lose apico-basal polarity and 
Figure 8: Schematic representation of the biological and molecular effects triggered by depletion of PDGFRα in GBM 
p-CSC2.
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gain properties of mesenchymal cells, and become motile 
and invasive [29–31].
PDGFRα-depleted CSC revealed the concomitant 
upregulation of angiogenic and survival pathways 
apparently in contrast with the downmodulation of 
endothelial markers such as VEGFR2, PECAM1 and VE-
Cadherin. We hypothesize that GBM CSC counteracted 
angiogenic inhibitory signals by activation of progrowth 
and prosurvival signals, which comprise PDGF-C, 
PDGF-D, EDNRB/EDN1/PRKCB1, Bcl-2/Bcl-xL and 
extracellular signal-regulated kinase (Erk1/2) signaling 
pathways [8, 32–36]. Several studies have demonstrated 
that PDGF-C and PDGF-D expression were ubiquitous in 
brain tumor cells and tissues but were very low or absent 
in normal adult and fetal brain [35]. High levels of those 
soluble factors in glioma specimens are associated with 
more rapid disease recurrence and poorer overall survival 
[35]. PDGF-C has been reported to induce angiogenic 
activity indirectly, via upregulation of VEGF and directly, 
via activation of PDGFRα. In particular, PDGF-C plays 
an important role in glioma vessel maturation and 
permeability, and can attenuate the response and escape 
from anti-VEGF therapy [35]. In vitro studies reported that 
inhibition of Bcl-2/Bcl-xL, along with an antitumor agent 
that induces TRAIL pathway-mediated cell death give a 
strong synergistic anti-proliferative effect on pediatric, 
adult, proneural GBM and glioma stem-like cells [36]. 
Our data support the existence of autocrine and paracrine 
signals and implicate for a role of PDGF-C, -D and EDN1 
signaling in GBM tumor growth. Liu and colleagues 
reported that EDN3/EDNRB signaling is involved in 
maintaining GBM CSC migration, stemness and survival 
[33].
Dong et al. reported that the selective inhibition of 
PDGFR by the Imatinib, a drug analog of Crenolanib, 
elicited the activation of Erk1/2 in malignant glioma cells. 
The activation of Erk1/2 induced by the Imatinib treatment 
was related to the S-phase re-entry of the cell cycle in 
one of the three glioma cells tested [38]. Evenly the up 
regulation of CycD1 observed in PDGFRα-depleted cells 
compared to pLKO.1, particularly evident at 4th day of 
differentiation, would agree with the presence of autocrine 
and paracrine mitogenic stimuli as argued previously. The 
overall results reinforce the rationale of using combined 
anti-angiogenic and multiple approaches to improve the 
therapeutic response for GBM [39, 35, 9].
Tam and colleagues reported that PKCα 
overexpression upregulates AP1, which in turn mediates 
Notch4 activity [40]. Activated Notch4 is closely 
associated with the promotion of estrogen-independence 
and chemotherapy resistance in breast cancer cells. In 
different cell contexts such as intestinal, pancreatic and 
mammary cells, PKCα has anti-proliferative effects [41]. 
PKCα is a downstream target of PDGFR signaling and 
despite the constitutive phosphorylation on T638-641, it 
does not appear to be modulated at transcriptional level in 
proliferation and differentiation conditions. Nevertheless, 
we hypothesized that PKCα could be involved in 
stemness regulation in GBM CSC, but unexpectedly we 
noticed no significant modulation of the multipotency 
stem cell markers Nestin and Sox2 in PKCα-depleted 
CSC as compared to parental cells. Further experiments 
needed to clarify the role of PKCα in the maintenance, 
invasiveness and differentiation of GBM CSC. Our 
data led us to assume a compensatory mechanism as 
described formerly because of the increase of PRKCB1 
gene expression, however this result is not consistent 
with the levels of T638-641 phosphorylation of PKCβII 
isoform and we think that the issue should be addressed in 
details. For PKCβ isoforms there are conflicting reports, 
as some indicate PKCβ expression, while others not [42]. 
Clinical studies have evaluated the acceptable tolerability 
of enzastaurin (an inhibitor of PKCβ and PI3K/AKT) in 
patients with recurrent GBM, but the authors reported 
that it did not have a superior efficacy of the alkylating 
agent Lomustine [43, 44]. However, there is a paucity of 
data on the role of PKCβ isoforms in CSC and further 
experiments are required to reveal their role in glioma 
pathogenesis.
We have reported the up regulation of RB1 at 
transcriptional and protein level in its active state 
in PDGFRα-depleted CSC either in proliferating or 
differentiated CSC, which correlated with Stat3 activity 
decline. Our data reported for the first time that the 
PDGFRα/PDGF-AA axis is a regulator of the crosstalk 
between Stat3 and Rb1 signals. In the current study, 
Stat3 seems to play a dual role as oncogene and tumor 
suppressor in GBM CSC. Evidences from the literature, 
report Stat3 persistently phosphorylated and associated 
with an unfavorable prognosis in GBM. In the current 
study, the markers of neural stem cell multipotency 
decrease as much as Stat3 activity decreased upon 
PDGFRα inhibition, suggesting that Stat3 is required 
for maintenance of the stem-like features of these cells 
[1, 13]. Furthermore, JAK-Stat signaling pathway 
selectively enhanced differentiation of neural stem cells 
towards a glial lineage and inhibited differentiation of 
neural precursors along a neuronal lineage [11, 12]. 
Here we show that the upregulation of Stat3 activity 
during GBM CSC differentiation is consistent with 
higher levels of GFAP with respect to PDGFRα-depleted 
cells, which instead revealed a decrease of GFAP and 
NG2 expression and the early activation of neuronal 
marker MAP2a/b in proliferating cells [27]. Besides a 
role of PDGFRα in glial differentiation, the block of 
PDGFRα activity in vitro promoted the reduction of 
NG2 expression and tumor cells growth as reported by 
Pilkington [45]. Accordingly Chekenya et al. described 
that the grafting of NG2+ve GBM cell lines displayed 
an in vivo growth advantage, which was associated with 
tumor angiogenesis [46].
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The Rb1 pathway is altered in almost 70% of 
human cancer types and this pathway is mutated in 78% 
of cases of GBM. Ichimura et al. reported that among 
120 GBM, 40% had no wild-type CDKN2A gene, 12% 
amplified the CDK4 gene, and 14% had no wild-type 
RB1 gene [47], and the majority of the GMB (64%) 
had only one of these abnormalities [48]. Nakamura et 
al. reported that 93% of tumors with Rb1 expression 
had a normal RB1 gene status [49]. In our paper, we 
reported higher expression of RB1 gene transcription and 
hypophosphorylated Rb1 protein in PDGFRα-depleted 
GBM CSC compared to control cells, thus on the basis 
of the literature, we could assume that RB1 gene most 
likely has a normal status. On the other hand, we could 
not rule out CDKN2A and CDK4 gene alterations. 
In addition, the complexity of Rb1 pathway is often 
accompanied by gain-of-function of p53, resulting in 
dysregulation of tightly regulated cellular processes such 
as cell cycle, upregulation of survival and oncogenic 
signals as observed in our PDGFRα-depleted GBM CSC 
[50]. Several preclinical and clinical studies aimed to 
inhibit the CDK4/CDK6 kinase activity as components 
that lead to Rb1 inactivation by hyperphosphorylation, 
and consequent suppression of cell cycle arrest [51–53]. 
We assumed that the Rb1 gene activation detected in 
PDGFRα-depleted GBM CSC clones would promote 
anti-proliferative and anti-apoptotic effects and along 
with Stat3 might induce the molecular profile change 
observed in differentiated PDGFRα-depleted GBM 
CSC. Rb1 is also involved in other cellular processes 
such as the induction of terminal cellular differentiation, 
maintenance of genetic stability, protection from 
apoptotic insults in GBM and cancer stem cells [19, 48, 
50–53].
After all we found that the inhibition of a single 
molecular target by a genetic approach or the application 
of receptor tyrosine kinase inhibitor as a single drug 
could provoke adaptive effects in tumor cells such as 
the activation of compensatory oncogenic signals [38]. 
Therefore, combination therapies could be a better way 
to kill tumor stem cells. As an example, Ziegler et al., 
demonstrated that the inhibition of PDGFR in human 
glioblastoma cells, is counteracted by inhibitor of 
apoptosis proteins (IAP), and concomitant inhibition of 
PDGFR with inactivation of IAPs resulted in increased 
apoptosis [38, 49].
Further experiments should be addressed to unveil 
the molecular mechanisms underlying the molecular 
crosstalk between Rb1 and Stat3 pathways directed by 
PDGFRα/PDGFAA axis in GBM CSC. In fact, clinical 
trials are ongoing to target PDGFR amplification or Stat3 
activity in patients with malignant gliomas. Unfortunately, 
the results of these clinical trials are not yet available, so 
it is early to draw conclusions. We hypothesize that the 
newly discovered PDGFRα/Stat3/Rb1 regulatory axis 




Procedures for collection of adult human GBM CSC 
were approved by the Ethical Committee of the Catholic 
University of Rome as reported previously [24, 25]. The 
informed consent was obtained and all patients were fully 
aware of the aims and scope of this work. The ethical 
principles of the declaration of Helsinki, were strictly 
followed [24, 25].
Cell culture of human glioblastoma cancer stem 
cells
We have used the same clinical materials reported 
in our previous papers [24]. In brief, the CSC cells were 
retrieved from adult patients affected by GBM and 
undergoing craniotomy at the Institute of Neurosurgery, 
Catholic University-School of Medicine of Rome, 
Italy. Dissociated cells were cultured in proliferation 
medium containing human recombinant EGF (20 ng/ml; 
PeproTech, Rocky Hill, NJ), human recombinant bFGF 
(10 ng/ml; PeproTech), in DMEM/F12 (1:1) serum-
free medium (Invitrogen, Carlsband, CA) as reported 
previously [24]. Floating neurospheres were dissociated 
with Accutase at 37°C (Merck-Millipore). Neurospheres 
culture were passaged up to passage P30 and the 
experiments were performed between P20 and P30.
shRNA, transfection and lentivirus production
Experiments of RNA interference are carried out 
using Mission Lentivirus-based shRNA for PDGFRα 
(NM_006206-Sigma-Adrich) and PKCα (NM_002737.2-
Sigma-Aldrich) as reported previously [24]. We selected 
several puromycin resistant PDGFRα-directed shRNA cell 
clones (shPDGFRα-CSC cl.1, 3), but only two significantly 
targeted PDGFRα expression (TRCN0000195132/
clone 1 and TRCN0000196928/clone 3. Similarly, we 
selected GBM CSC clones expressing shRNA for PKCα 
(TRCN0000233511 and TRCN0000233513).
Western blots
GBM CSC are seeded as single cells (1x106/p90 
dish) in proliferation medium, and collected 2-3 days 
later for Western blot analysis. Afterwards, cells were 
collected and washed with PBS containing proteases 
inhibitors before protein extraction in 100-150μl of 
lysis buffer (1% NP-40, 0.01% SDS, 20 mM Tris–HCl 
pH 7.4, 300 mM NaCl, 1 mM EDTA, 1 mM Na3VO4 
and protease inhibitors cocktail from Sigma–Aldrich). 
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Then, cells were sonicated with two pulses of 5 sec at 
50% of amplitude (Sonics and Materials, Newtown, 
CT). Equal amounts (30μg/lane) of total protein 
extracts, quantified by Bio-Rad protein Assay (Bio-Rad, 
Munchen, Germany), were loaded on PAGE Bis-Tris gels 
(FISHER), and transferred on Hybond-P Extra membrane 
(Amersham Biosciences, GE Healthcare Life Science-
Buckinghamshire, UK). Filters were immunoblotted 
using the following primary antibodies: rabbit anti-
EGFR, rabbit anti-Y1068-EGFR, goat anti-PDGFRα, 
rabbit anti-T202/Y204-ERK1/2 and anti-ERK1/2, 
rabbit anti-Y705-STAT3 and rabbit anti-STAT3, rabbit 
anti-T638/641-PKCα/βII, rabbit anti-PCKα, rabbit anti-
VEGFR2 (all purchased from Cell Signaling, MA-USA), 
mouse anti-underphosphorylated Rb1 (BD Pharmigen), 
Rabbit anti-Rb1 (Cell Signaling), mouse anti-BCL-2 
(Dako), mouse anti-Nestin (Millipore), mouse anti-
GFAP (Covance), rabbit anti-NG2 (Chemicon), mouse 
anti-MAP2a/b and rabbit anti-OCT4 (Millipore), rabbit 
anti-BCL-x/L, rabbit anti-CycD1, rabbit anti-SOX2, 
rabbit anti-BMI1 and rabbit anti-EGR1, rabbit anti-
CD31, goat anti-VE-Cadherin (Santa Cruz-USA), 
mouse anti-β-actin (SIGMA). After three washing with 
TBS-Tween buffer, immuno-reactive proteins were 
detected using rabbit anti-mouse, donkey-anti-rabbit 
and donkey anti-goat horseradish peroxidase-conjugated 
secondary antibodies directed to the appropriate primary 
antibodies (Jackson Immunoresearch Laboratories, West 
Grove, PA). The proteins were then visualized using the 
chemiluminescence system (Millipore). Gels and images 
acquisition were done by HP Photosmart Essential 
Ver. 1.12 and Adobe Photoshop CS5 respectively. The 
densitometric analysis of protein bands normalized 
against to β-actin protein levels was performed from 
two independent experiments using the ImageJ software 
(NIH, USA).
Cell proliferation, differentiation and 
pharmacological treatment of GBM CSC
To monitor neurospheres formation of shPDGFRα-
CSC vs control cells (pLKO.1), cells are dissociated into 
single cells and 1x104 cells/well were plated in triplicate 
on 6-well dishes. Cells are imaged in phase-contrast 
after 3 and 7 day in growth medium using an Olympus 
CX41 microscope with 20X/10X objectives. For cell 
differentiation, cells were dissociated in single cells and 
plated onto matrigel-coated 100 mm dishes in presence of 
5% fetal calf serum (FCS) for 1, 2 and 4 days. To assess 
the effects of pharmacological treatments, time course 
experiments were conducted on cells undergone to growth 
factors withdrawal for 2 days and then stimulated with 
exogenous PDGF-AA (Peprotech) alone or combined 
with 10μM of Crenolanib (CP-868,596; Selleckchem), 
for different time points (5-10-30-120 minutes until 24 
hours).
RT-qPCR assay
Total RNA was extracted using Triazol and by 
RNeasy mini kit (Qiagen, USA). cDNAs were obtained 
using QuantiTect Reverse Transcription kit (Qiagen, 
USA). Quantitative Real Time Reverse Transcriptase 
PCR (RT-qPCR) was conducted in triplicate using SYBR 
Hi-ROX kit (Bioline, UK). RT-qPCR was performed 
with a 7900HT instrument equipped with SDS2.2 
software (Applied Biosystems, CA). The sequences 
of oligonucleotides used for RT-qPCR were described 
in Table 1. The Fold change (Fc) were obtained by 
normalization of RNAs expression respect to selected 
housekeeper genes (GAPDH, TBP) and respect to pLKO.1 
cells.
Cell invasion assay
For the invasion assay, 1x105 cells resuspended 
in 0.3 ml of Stem Medium and placed in triplicate into 
the top chamber of 150μl matrigel-coated transwell 
insert (Millipore). The bottom wells contained 0.4 ml of 
stem medium as control or stem medium with PDGF-
AA or EGF (50 ng/ml) as chemoattractant. After 48h, 
cells on the top surface of the filter are removed with a 
cottonswab. Thereafter, the filters are fixed and stained 
with 0.5% of crystal violet and subsequently washed to 
collect the staining solution. OD values, proportional to 
the number of cells, are measured by a plate reader at 
590 nm (Bio-Rad). These experiments were performed 
twice and each time in triplicate. The absorbance values 
were calculated as mean ± SD (n=3) of two different 
experiments.
Statistical analysis
Statistical analysis was performed with Prism5 
(GraphPad) and Microsoft Office Excel 2013. All 
data shown are representative of results obtained from 
two independent experiments conducted in triplicate. 
The results were analyzed by Two-way ANOVA and 
Bonferroni’s post tests. Data are expressed as mean ± SD 
(n=3) of 2 independent experiments, and P values ≤0.05 
(*), ≤0.01(**), ≤0.001 (***) were considered statistically 
significant.
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Table 1: List of primers for RT-PCR analysis
Gene ID Name  Sequences 5’→3’
NM_001128128.2 hZEB1 For ATGACCTGCCAACAGACCAG
  Rev TTGCCCTTCCTTTCCTGTGT
NM_001171653.1 hZEB2 For AAGCCTCTGTAGATGGTCCAG
  Rev GTCACTGCGCTGAAGGTACT
NM_003380.3 hVIM For AGAGGAAGCCGAAAACACCC
  Rev TCAAGGTCAAGACGTGCCAG
NM_000474.3 hTWIST For TCAAGAGGTCGTGCCAATCA
  Rev ATGGTTTTGCAGGCCAGTTT
NM_001166055.1 hEDNRA For GAGGTTTTCTGAAGCCGGGG
  Rev TGTGCTGCTTTTACACCTTCAC
NM_000115.3 hEDNRB For TGCTTGCTTCATCCCGTTCA
  Rev GGCCAATGGCAAGCAGAAAT
NM_001168319.1 hEDN1 For TGAGAGGAAGAAAAATCAGAAGA
  Rev TTTCTCATGGTCTCCGACCT
NM_001306132.1 hFN1 For TGACAAGCAGACCAGCTCAG
  Rev CTGTCACACGAGCCCTTCTT
NM_001795.3 hCDH5 For ATGCGGCTAGGCATAGCATT
  Rev TGTGACTCGGAAGAACTGGC
NM_004360.3 hCDH1 For CGAGAGCTACACGTTCACGG
  Rev CTTTGTCGACCGGTGCAATC
NM_000442.4 hPECAM1 For TGATGCCGTGGAAAGCAGAT
  Rev GCATCTGGCCTTGCTGTCTA
NM_002253.2 hVEGFR2 For ACAGCAACTTGCAGGACAGT
  Rev GAGCTCGATGCTCACTGTGT
NM_003106.3 hSOX2 For AATAGCATGGCGAGCGGGG
  Rev CCGTTCATGTGCGCGTAACT
NM_001173531.2 hOCT4 For CTCGAGAAGGATGTGGTCCG
  Rev TAGTCGCTGCTTGATCGCTT
NM_000321.2 hRB1 For CTCACCTCCCATGTTGCTCA
  Rev GGGTGTTCGAGGTGAACCAT
NM_002737.2 hPRKCA For ATATGTCAACGGTGGGGACC
  Rev TCCGATGGAAATCTCTGCCG
NM_002738.6 hPRKCB1 For TCCAGCCCCCTTATAAGCCA
  Rev GATGGCGGGTGAAAAATCGG
NM_033023.4 hPDGFA For CGGATACCTCGCCCATGTTC
  Rev CGGATGCTGTGGATCTGACT
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